Research Collaboration with The Royal Marsden

AI SummaryClose X

CelLBxHealth plc has announced a research collaboration with The Royal Marsden NHS Foundation Trust to conduct a clinical study involving 200 patients with advanced non-small cell lung cancer. This study will focus on analyzing circulating tumor cell DNA (CTC-DNA) in patients whose circulating tumor DNA (ctDNA) testing is uninformative, aiming to identify actionable mutations that can guide treatment decisions for this cohort. Results are anticipated by year-end, with the potential to expand treatment options for a significant number of lung cancer patients.

Disclaimer*

UK 100

Latest directors dealings